期刊文献+

胆管癌的诊疗现状 被引量:3

The Diagnosis and Treatment Status of Cholangiocarcinoma
原文传递
导出
摘要 胆管癌是一类高度威胁人类健康的消化道恶性肿瘤,近年来,其全球发病率、死亡率显著增加。但由于发病隐匿而无法早期确诊,病因不明,治疗手段有限,有效的根治性切除率很低,并且术后肿瘤的复发率高,目前在治疗上仍是一个巨大的挑战。随着人们对其生物学特性的深入研究及诊断技术的进步,越来越多新的诊断、治疗方法被应用,人们对胆管癌的治疗理念也在不断的更新。 Cholangiocarcinoma is a serious threat to human health of digestive tract malignant tumor In recent years, the global incidence and mortality rate increased significantly, but as a result of the hidden, unknown etiology, limited treatment method, low effective radical resection rate, and high postoperative tumor recurrence rate, the treatment is still a great challenge. Along with the biological characteristics of the deep research and diagnostic technology progress, more and more new diagnosis, and treatment methods are applied, the treatment concept is also under constant updates.
出处 《现代生物医学进展》 CAS 2015年第2期368-372,397,共6页 Progress in Modern Biomedicine
基金 兰州大学中央高校基本科研业务费专项基金(lzujbky-2013-139) 西北高原地区高发恶性肿瘤发生的环境与遗传机理研究(lzujbky-2013-m04)
关键词 胆管癌 诊断 治疗 肝移植 生物治疗 Cholangiocarcinoma Diagnosis Treatment Liver transplantation Biological therapy
  • 相关文献

参考文献50

  • 1Charbel H, A1-Kawas F H. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis[J]. Curr Gastroenterol Rep, 2011, 13(2): 182-187.
  • 2Fabris L, Alvaro D. The prognosis of perihilar cholangiocarcinoma after radical treatments[J]. Hepatology, 2012, 56(3): 800-802.
  • 3Hirano S, Kondo S, Tanaka E, et al. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality[J]. J Hepatobiliary Panereat Sei, 2010, 17(4): 455-462.
  • 4Farges O, Fuks D, Le Treut Y P, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group[J]. Cancer, 2011, 117(10): 2170-2177.
  • 5Charbel H, A1-Kawas F H. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis[J]. Curr Gastroenterol Rep,2011, 13(2): 182-187.
  • 6Gatto M, Alvaro D. Cholangiocarcinoma: risk factors and clinical presentation[J]. Eur Rev Med Pharmacol Sci, 2010, 14(4): 363-367.
  • 7Li C, Wang W, Ding H, et al. Value of contrast-enhanced sonography in the diagnosis of peripheral intrahepatic cholangiocarcinoma [J]. J Clin Ultrasound, 2011, 39(8): 447-453.
  • 8Foley W D, Quiroz F A. The role of sonography in imaging of the biliary tract[J]. Ultrasound Q, 2007, 23(2): 123-135.
  • 9Matsusaki S, Kikuyama M, Kawakami H, et al. Clinical features and CT findings in the differential diagnosis of IgG4-related sclerosing cholangitis and cholangiocarcinoma [J]. Nihon Shokakibyo GakkaiZasshi, 2013, 110(4): 615-621.
  • 10Cameron K, Golan S, Simpson W, et al. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT)[J]. Abdom Imaging, 2011, 36(4): 463-471.

同被引文献27

  • 1Luo XW, Yuan L,Wang Y, et al. Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma:a large Single- Center cohort study[J]. Gastrointesti Surg, 2014,18 (3) : 562-572.
  • 2Graziano F, Catalano V, Lorenzini P, et al. Clinical impact of the HGF/Met pathway activation in patients with ad- vanced gastric cancer treated with palliative chemotherapy [J]. Pharmaeogenomics J,2014,14(5) :418-423.
  • 3Sano Y, Hashimoto E,Nakatani N,et al. Combining onar- tuzumab with erlotinib Inhibits growth of non sma[I ceillung cancer with activating EGFR mutations and HGF overexpression[J]. Molecular Cancer Therapeutics, 2014, 14(2) : 533-541.
  • 4Leelawat K, Leelawat S, Tepaksorn P, et al. Involvement of c-Met/hepatocyte growth factor pathway in cholangio- carcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for C-Met[J]. J Surg Res, 2006,136 (1) : 78-84.
  • 5Braconi C, Valeri N, Gasparini P, et al. Transcribed ultra- conserved regions are aberrantly expressed and can be modulated by interleukin 6 in cholangiocarcinoma [J]. Lancet,2013 ,Supple 1:26.
  • 6Patel T. New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma[ J ]. J GastroenteroI, 2014,49(2) : 165-172.
  • 7Seiwert TY,Beck TN,Salgia R. The role of HGF/c MET in head and neck squamous cell carcinoma[M]//molecu- lar determinants of head and neck cancer. Springer New York, 2014 : 91-111.
  • 8Sims JD,Taguiam JM, Hanson C, et al. A novel tumo targeting construct aimed at cMet[J]. Cancer Res,2014, 74(19 SuppD :4490.
  • 9Tijeras-Raballand A, Serrate C, Riveiro ME, et al. Met in hibition using SUl1274 impairs cellular activities in hepa tocellular and Cholangiocarcinomas with high levels of Met and low levels of EGFR expressions[J]. Cancer Res, 2013,73(8 Suppl) ..2178-2178.
  • 10Balaban YH ,Us D, Haseelik G, et al. Hepatocellular car cinoma and cholangiocarcinoma are associated with high serum levels of hepatocyte growth factor[J]. Indian J Gastroenterol, 2006,25 (4) : 223.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部